STOCK TITAN

Bio-Techne (TECH) CEO exercises 36,500 options and uses 32,088 shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.

To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.

Positive

  • None.

Negative

  • None.
Insider Kelderman Kim
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 36,500 $0.00 --
Exercise Common Stock 36,500 $0.00 --
Tax Withholding Common Stock 32,088 $58.66 $1.88M
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Performance Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Performance Stock Options (Right to Buy) -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
holding Performance Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Stock Options (Right to Buy) -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 73,036 shares (Direct); Common Stock — 85,165 shares (Direct); Stock Options (Right to Buy) — 28,940 shares (Direct); Performance Restricted Stock Units — 8,873 shares (Direct); Performance Stock Options (Right to Buy) — 23,881 shares (Direct); Restricted Stock Units — 17,087 shares (Direct)
Footnotes (1)
  1. Fully exercisable. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Options exercised 36,500 shares Stock options exercised at $47.60 on April 14, 2026
Exercise price $47.60/share Conversion price for 36,500 stock options
Tax-withholding shares 32,088 shares Shares withheld for tax liability at $58.66/share
Tax-withholding price $58.66/share Value used for F-code tax-withholding disposition
Shares owned after transaction 53,077 shares Direct common stock holdings following Form 4 transactions
Largest remaining option grant 115,724 underlying shares Options at $66.97 expiring August 5, 2027
Long-dated option grant 90,441 underlying shares Options at $53.60 expiring August 15, 2035
Performance RSUs block 70,708 underlying shares Performance restricted stock units with zero exercise price
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with an exercise price of 47.6000"
Performance Restricted Stock Units financial
"Performance Restricted Stock Units with an exercise price of 0.0000"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Restricted Stock Units representing rights to receive common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelderman Kim

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/14/2026M36,500A$085,165D
Common Stock04/14/2026F32,088D$58.6653,077D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$47.604/14/2026M36,500 (1)08/07/2026Common Stock36,500$073,036D
Stock Option (Right to Buy)$66.97 (1)08/05/2027Common Stock115,724115,724D
Stock Option (Right to Buy)$120.46 (1)08/06/2028Common Stock25,94425,944D
Stock Options (Right to Buy)$94.52 (1)08/15/2029Common Stock28,94028,940D
Performance Restricted Stock Units(2) (3) (3)Common Stock8,8738,873D
Performance Stock Options (Right to Buy)$84.61 (3)08/15/2030Common Stock23,88123,881D
Stock Options (Right to Buy)$84.61 (4)08/15/2030Common Stock29,39129,391D
Stock Options (Right to Buy)$52.83 (5)11/01/2030Common Stock38,25238,252D
Performance Restricted Stock Units(2) (3) (3)Common Stock9,4239,423D
Performance Stock Options (Right to Buy)$68.54 (3)02/01/2031Common Stock25,94525,945D
Stock Options (Right to Buy)$68.54 (6)02/01/2031Common Stock51,89051,890D
Performance Restricted Stock Units(2) (7) (7)Common Stock51,26151,261D
Restricted Stock Units(2) (8) (8)Common Stock17,08717,087D
Stock Options (Right to Buy)$74.91 (9)08/15/2034Common Stock69,06169,061D
Performance Restricted Stock Units(2) (10) (10)Common Stock70,70870,708D
Restricted Stock Units(2) (11) (11)Common Stock35,35435,354D
Stock Options (Right to Buy)$53.6 (12)08/15/2035Common Stock90,44190,441D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
4. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
6. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.04/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BIO-TECHNE (TECH) CEO Kim Kelderman do in this Form 4?

Kim Kelderman exercised stock options for 36,500 shares of Bio-Techne common stock at an exercise price of $47.60 per share. These options were fully exercisable and converted into common shares as part of his equity compensation package.

Were any BIO-TECHNE (TECH) shares sold on the open market in this filing?

The filing shows a tax-withholding disposition of 32,088 shares at $58.66 per share. This represents shares withheld to satisfy tax obligations, not an open-market sale initiated by the CEO to reduce his investment position.

How many BIO-TECHNE (TECH) shares does the CEO hold after these transactions?

Following the option exercise and tax withholding, Kim Kelderman directly owns 53,077 shares of Bio-Techne common stock. This figure reflects his updated equity stake after the Form 4 transactions reported for the date of April 14, 2026.

What stock options remain outstanding for the BIO-TECHNE (TECH) CEO after this Form 4?

The derivative holdings show multiple remaining option grants, including 115,724 underlying shares at an exercise price of $66.97 expiring on August 5, 2027. Additional option awards with different exercise prices and expirations also remain unexercised.

Does BIO-TECHNE (TECH) CEO Kim Kelderman hold restricted stock units?

Yes. The filing lists various restricted stock units and performance restricted stock units tied to Bio-Techne common stock, such as 51,261 performance RSUs and 35,354 RSUs, which vest over future dates if service or performance conditions are met.

How many shares were used to cover taxes in the BIO-TECHNE (TECH) CEO’s transaction?

The Form 4 reports 32,088 shares of common stock with a transaction code F, described as payment of tax liability by delivering securities at $58.66 per share. This mechanism satisfies tax obligations instead of using cash.